KRAS Inhibitor Daraxonrasib Shows Promise in Pancreatic Cancer
Revolution Medicines' daraxonrasib shows meaningful responses in KRAS-mutant pancreatic cancer in Phase 2 data, marking a breakthrough in a notoriously hard-to-treat disease.
3 articles tagged "Revolution Medicines"
Revolution Medicines' daraxonrasib shows meaningful responses in KRAS-mutant pancreatic cancer in Phase 2 data, marking a breakthrough in a notoriously hard-to-treat disease.
Revolution Medicines closed a $2 billion raise after Phase 3 data showed daraxonrasib doubled median overall survival in advanced pancreatic cancer.
Revolution Medicines' daraxonrasib nearly doubled median survival in metastatic pancreatic cancer patients compared to chemotherapy, according to new data.